Tags

Type your tag names separated by a space and hit enter

Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
West Afr J Med. 2011 Sep-Oct; 30(5):319-24.WA

Abstract

BACKGROUND

Hyperhomocysteinaemia (HHcy) is as a long-term sequelum of levodopa therapy in Parkinson's disease (PD). Information on its frequency and effects in Africans with PD is sparse.

OBJECTIVE

To determine the frequency of HHcy and its relationship to clinical features of PD in African patients.

METHODS

Using a case-control design, 40 consecutively attending PD patients and 40 age- and gender-matched healthy volunteering controls were studied. Parkinson's disease cases were evaluated for disease and treatment characteristics, using the Unified Parkinson Disease Rating Scale (UPDRS) motor and activities of daily living scores and disease stage (Hoehn and Yahr scale). Fasting total plasma homocysteine (Hcy) was determined in all subjects. Hyperhomocysteinaemia was defined as a Hcy level above the 90th percentile for the controls.

RESULTS

Mean Hcy was 13.8 ± 5.4mmol/L in PD and 12.4±3mmol/L in controls (P>0.05). Hyperhomocysteinaemia (Hcy > 16.26umol/L) occurred in nine (22.5%) PD patients (all on levodopa) and 6 (15%) controls (P>0.05). Mean duration of levodopa use was 92 ± 105.3 months in PD with HHcy compared to PD patients with normal Hcy 33.9 ± 33.2 (p < 0.05). Disease severity and disability were similar regardless of Hcy levels. None of current age, disease duration, Hoehn and Yahr stage, UPDRS scores, total levodopa dose and duration was independent predictor of homocysteine level.

CONCLUSION

There is increased occurrence of hyper-homocysteinaemia in Nigerian subjects with Parkinson's disease, receiving Levodopa. This hyperhomocysteinaemia is more common with prolonged use but appears to have no relationship with disease severity or disability.

Authors+Show Affiliations

Neurology Unit,Department of Medicine, College of Medicine,University of Lagos. PMB 12003, Idi Araba, Lagos,Nigeria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22752818

Citation

Ojo, O O., et al. "Plasma Homocysteine Level and Its Relationship to Clinical Profile in Parkinson's Disease Patients at the Lagos University Teaching Hospital." West African Journal of Medicine, vol. 30, no. 5, 2011, pp. 319-24.
Ojo OO, Oladipo OO, Ojini FI, et al. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital. West Afr J Med. 2011;30(5):319-24.
Ojo, O. O., Oladipo, O. O., Ojini, F. I., Sanya, E. O., Danesi, M. A., & Okubadejo, N. U. (2011). Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital. West African Journal of Medicine, 30(5), 319-24.
Ojo OO, et al. Plasma Homocysteine Level and Its Relationship to Clinical Profile in Parkinson's Disease Patients at the Lagos University Teaching Hospital. West Afr J Med. 2011 Sep-Oct;30(5):319-24. PubMed PMID: 22752818.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital. AU - Ojo,O O, AU - Oladipo,O O, AU - Ojini,F I, AU - Sanya,E O, AU - Danesi,M A, AU - Okubadejo,N U, PY - 2012/7/4/entrez PY - 2012/7/4/pubmed PY - 2014/4/23/medline SP - 319 EP - 24 JF - West African journal of medicine JO - West Afr J Med VL - 30 IS - 5 N2 - BACKGROUND: Hyperhomocysteinaemia (HHcy) is as a long-term sequelum of levodopa therapy in Parkinson's disease (PD). Information on its frequency and effects in Africans with PD is sparse. OBJECTIVE: To determine the frequency of HHcy and its relationship to clinical features of PD in African patients. METHODS: Using a case-control design, 40 consecutively attending PD patients and 40 age- and gender-matched healthy volunteering controls were studied. Parkinson's disease cases were evaluated for disease and treatment characteristics, using the Unified Parkinson Disease Rating Scale (UPDRS) motor and activities of daily living scores and disease stage (Hoehn and Yahr scale). Fasting total plasma homocysteine (Hcy) was determined in all subjects. Hyperhomocysteinaemia was defined as a Hcy level above the 90th percentile for the controls. RESULTS: Mean Hcy was 13.8 ± 5.4mmol/L in PD and 12.4±3mmol/L in controls (P>0.05). Hyperhomocysteinaemia (Hcy > 16.26umol/L) occurred in nine (22.5%) PD patients (all on levodopa) and 6 (15%) controls (P>0.05). Mean duration of levodopa use was 92 ± 105.3 months in PD with HHcy compared to PD patients with normal Hcy 33.9 ± 33.2 (p < 0.05). Disease severity and disability were similar regardless of Hcy levels. None of current age, disease duration, Hoehn and Yahr stage, UPDRS scores, total levodopa dose and duration was independent predictor of homocysteine level. CONCLUSION: There is increased occurrence of hyper-homocysteinaemia in Nigerian subjects with Parkinson's disease, receiving Levodopa. This hyperhomocysteinaemia is more common with prolonged use but appears to have no relationship with disease severity or disability. SN - 0189-160X UR - https://www.unboundmedicine.com/medline/citation/22752818/Plasma_homocysteine_level_and_its_relationship_to_clinical_profile_in_Parkinson's_disease_patients_at_the_Lagos_University_Teaching_Hospital_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -